hydroxychloroquine has been researched along with Behcet Syndrome in 4 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Behcet Syndrome: Rare chronic inflammatory disease involving the small blood vessels. It is of unknown etiology and characterized by mucocutaneous ulceration in the mouth and genital region and uveitis with hypopyon. The neuro-ocular form may cause blindness and death. SYNOVITIS; THROMBOPHLEBITIS; gastrointestinal ulcerations; RETINAL VASCULITIS; and OPTIC ATROPHY may occur as well.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 37-year-old female patient experienced oral ulcer and erythema nodosum on the right leg for over 12 months and resisted to Methylprednisolone and Thalidomide." | 4.12 | Refractory Behçet's disease treated with low-dose interleukin-2: A case report. ( He, J; Liu, T; Xiao, X; Zhou, W, 2022) |
| "Favipiravir was the most prescribed drug (74." | 1.72 | The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome. ( Atli, Z; Aydin, T; Balkan, II; Fresko, I; Hamuryudan, V; Hatemi, G; Melikoglu, M; Ozcifci, G; Ozguler, Y; Oztas, M; Seyahi, E; Tabak, F; Ugurlu, S, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ozcifci, G | 1 |
| Aydin, T | 1 |
| Atli, Z | 1 |
| Balkan, II | 1 |
| Tabak, F | 1 |
| Oztas, M | 1 |
| Ozguler, Y | 1 |
| Ugurlu, S | 1 |
| Hatemi, G | 1 |
| Melikoglu, M | 1 |
| Fresko, I | 1 |
| Hamuryudan, V | 1 |
| Seyahi, E | 1 |
| Zhou, W | 1 |
| Liu, T | 1 |
| Xiao, X | 1 |
| He, J | 1 |
| Muruganandam, M | 1 |
| Rolle, NA | 1 |
| Sibbitt, WL | 1 |
| Cook, GB | 1 |
| Emil, NS | 1 |
| Fangtham, M | 1 |
| Reiter, KJ | 1 |
| Bankhurst, AD | 1 |
| Singer, NG | 1 |
| McCune, WJ | 1 |
1 review available for hydroxychloroquine and Behcet Syndrome
| Article | Year |
|---|---|
Update on immunosuppressive therapy.
Topics: Adult; Arthritis, Juvenile; Azathioprine; Behcet Syndrome; Child; Cladribine; Cyclophosphamide; Cycl | 1998 |
3 other studies available for hydroxychloroquine and Behcet Syndrome
| Article | Year |
|---|---|
The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Behcet Syndrome; Comorbidity; COVID-19; COVID-19 Drug T | 2022 |
Refractory Behçet's disease treated with low-dose interleukin-2: A case report.
Topics: Adult; Behcet Syndrome; Erythema Nodosum; Female; Humans; Hydroxychloroquine; Interleukin-2; Methylp | 2022 |
Characteristics of Behcet's Disease in the American Southwest.
Topics: Adult; Behcet Syndrome; Cross-Sectional Studies; Enzyme Inhibitors; Female; Humans; Hydroxychloroqui | 2019 |